863111-00-6

Basic information

• Product Name: 4-(2,4-difluorophenyl)-1,2,3,6-tetrahydropyridine
• Synonyms: 4-(2,4-difluorophenyl)-1,2,3,6-tetrahydropyridine
• CAS NO: 863111-00-6
• Molecular Formula: C₁₁H₁₁F₂N
• Molecular Weight: 195.2085464
• Mol File: 863111-00-6.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(2,4-difluorophenyl)-1,2,3,6-tetrahydropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2,4-difluorophenyl)-1,2,3,6-tetrahydropyridine(863111-00-6)
• EPA Substance Registry System: 4-(2,4-difluorophenyl)-1,2,3,6-tetrahydropyridine(863111-00-6)

Safety Data

• Hazardous Substances Data: 863111-00-6(Hazardous Substances Data)

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 348-57-2 2,4-difluorobromobenzene 
• 941711-19-9 4-(2,4-difluoro-phenyl)-4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 291289-50-4 4-(2,4-difluorophenyl)piperidine 

Relevant articles and documents

(4-PHENYL-PIPERIDIN-1-YL)-[5-1H-PYRAZOL-4YL)-THIOPHEN-3-YL]-METHANONE COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)- [5-(1 H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit 11 β-hydroxysteroid dehydrogenase type 1 (11 β-HSD1 ). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 1 1 β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11 β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF

The present invention can provide a cancer treatment drug containing, as an active ingredient, a substance selected from the group consisting of an indazole compound of the following formula (I), a pharmaceutically acceptable salt, a hydrate, a water adduct and a solvate: